Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The investigators will add weekly cetuximab (c225) to the standard care of chemoradiation
against locoregionally advanced Nasopharyngeal Carcinoma (NPC), and evaluate the toxicity and
efficacy of this new regimen.